



24

DEC - 9 2002

Commissioner for Patents
Washington, DC 20231
www.uspto.gov

In re Application of
Alberto A. Gavizon, et al
Serial Number: 09/555,674
Filed: August 3, 2000
For: COMBINED CHEMO-IMMUNOTHERAPY WITH
LIPOSOMAL DRUGS AND CYTOKINES

WITHDRAWAL
FROM ISSUE

The purpose of this communication is to inform you that the above-identified application is being withdrawn from issue pursuant to 37 CFR 1.313.

The application is being withdrawn to permit reopening of prosecution. The reasons therefore will be communicated to you by the examiner.

PTO records reveal that the issue fee has not been paid. If the issue fee has been submitted, the applicant may request a refund or may request that the fee be credited to a deposit account. However, applicant may wait until the application is either again found allowable or held abandoned. If the application is allowed, upon receipt of a new Notice of Allowance and Issue Fee Due, applicant may request that the previously submitted issue fee be applied toward payment of the issue fee in the amount identified on the new Notice of Allowance and Issue Fee Due. If the application is abandoned, applicant may request either a refund or a credit to a deposit account.

The application is being forwarded to the examiner for action.

A handwritten signature in cursive script, appearing to read "Bruce M. Kisliuk", is written over a horizontal line.

Bruce M. Kisliuk, Director
Technology Center 1600

Browdy and Neimark, P.L.L.C.
624 Ninth Street, NW
Suite 300
Washington, DC 20001-5303

cc: Allowed Files, PK3-910
Drafting Branch, PK3-910